Arvinas, Inc. (ARVN)
| Market Cap | 1.56B |
| Revenue (ttm) | 161.10M |
| Net Income (ttm) | -308.60M |
| Shares Out | 68.71M |
| EPS (ttm) | -4.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 744,028 |
| Open | 21.59 |
| Previous Close | 21.64 |
| Day's Range | 21.17 - 22.71 |
| 52-Week Range | 20.99 - 53.08 |
| Beta | 1.97 |
| Analysts | Strong Buy |
| Price Target | 61.08 (+169.19%) |
| Earnings Date | Oct 30, 2024 |
About ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration... [Read more]
Financial Performance
In 2023, Arvinas's revenue was $78.50 million, a decrease of -40.26% compared to the previous year's $131.40 million. Losses were -$367.30 million, 30.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for ARVN stock is "Strong Buy." The 12-month stock price forecast is $61.08, which is an increase of 169.19% from the latest price.
News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:...
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...
Arvinas, Inc. (ARVN) Q3 2024 Earnings Call Transcript
Arvinas, Inc. (NASDAQ:ARVN) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jeff Ball - Chief Financial Officer John Houston - Chief Executive Officer, President and...
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be prese...
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...
Undercovered Dozen: Spirit Airlines, HubSpot, Cigna, First Quantum Minerals +
We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. Polestar Automotive Holding is seen as continuing to struggle with missed targets, high losses, and debt ra...
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn.
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
– Preclinical data for ARV-393 presented at t he European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma –
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D.
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced ...
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List
Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and t...
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 cli...
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combinati...
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024...
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead...
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...
Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation
Arvinas' shares have experienced a significant increase, up more than 75% since November 2023, due to the success of its lead asset, vepdegestrant, in breast cancer studies. Arvinas entered into a str...
Arvinas inks over $1.0 billion deal with Novartis
Arvinas Inc (NASDAQ: ARVN) is in the green at writing after announcing a deal worth over $1.0 billion with Novartis (SWX: NOVN). Details of Arvinas – Novartis agreement Novartis will pay $150 million ...
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas' preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billio...
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - - Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) -
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the ...
Arvinas Announces Chief Financial Officer Transition
- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn.
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
– ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2) –
Arvinas and Pfizer's Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
-- Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC®) protein degrader designed to target and degrade the estrogen receptor (ER) protein -- NEW HAVEN, Conn. and NEW YORK, Feb....
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
NEW HAVEN, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...